The French chemist Henri Kagan, 95, and Japan’s Kenso Soai share this year’s Nobel Prize in Chemistry for showing how a tiny imbalance between mirror-image molecules can be amplified — insight that underpins modern drug manufacture and offers a chemical route to one of the oldest puzzles about the origin of life.
Hold up your hands and they look alike, yet no amount of turning will make a left hand fit a right-hand glove. Many molecules share this property, known as chirality: they exist as two mirror-image forms, called enantiomers, that are chemically identical in most respects but interact very differently with the chiral machinery of living cells. On Wednesday, 7 October, the Royal Swedish Academy of Sciences awarded the 2026 Nobel Prize in Chemistry to Henri B. Kagan of Université Paris-Sud in Orsay, France, and Kenso Soai of Tokyo University of Science “for the discovery of non-linear effects and autocatalysis in asymmetric organic synthesis”. The laureates share 12 million Swedish kronor.
“Henri Kagan and Kenso Soai have provided a solution to a chemical mystery that is over a century old,” said Heiner Linke, chair of the Nobel Committee for Chemistry, describing the reactions they developed as “spectacular”.
Life’s one-handed chemistry
The mystery is called homochirality. The amino acids that make up proteins are almost exclusively left-handed; the sugars in DNA and RNA are right-handed. Yet ordinary laboratory reactions that create a chiral centre from non-chiral ingredients produce a 50:50 mixture, known as a racemate. How, then, did life come to use only one hand?
In 1953 the Bristol physicist Charles Frank proposed a theoretical answer: if a reaction’s product could catalyse its own formation while suppressing its mirror image, a small random excess could snowball into near-total dominance. For decades no one could show such a reaction in practice.
Kagan’s amplification
Kagan, already celebrated for designing DIOP, one of the first effective chiral ligands for metal catalysts, made the decisive conceptual step in the mid-1980s. Chemists had assumed that a catalyst of imperfect purity — say, 60 per cent one hand and 40 per cent the other — would produce products with proportionally imperfect purity. Kagan and colleagues showed that this linear assumption could fail. Because catalyst molecules can pair up, and mixed left–right pairs may be less active than same-handed ones, a modest imbalance in the catalyst could yield a markedly larger imbalance in the product. He called this a non-linear effect. It became a diagnostic tool for understanding how catalysts work and a demonstration, in principle, that chemical systems can amplify chirality.
Soai’s self-copying reaction
Soai supplied the first real example of Frank’s idea. In a paper in Nature in 1995, his group described the addition of an organozinc reagent to a pyrimidine aldehyde, forming a chiral alcohol that itself catalyses the same reaction with a preference for its own handedness. Starting from a product enriched by only about 2 per cent in one form, the reaction reached roughly 87 per cent enrichment, and repeated cycles pushed it higher still. Later work showed that the reaction could be tipped one way or the other by minute chiral influences, including chiral crystals such as quartz and even isotopic differences. “Kagan showed how it could be done in principle and then the Soai reaction gave us the first actual real example,” the Bristol chemist Jonathan Clayden told Nature.
Soai, reached by the committee while shopping near his home, called the news “the most exciting day in my life”. Kagan’s former student Olivier Riant of the Catholic University of Louvain described him as “a very, very modest person with a real passion for chemistry”.
From origin of life to the pharmacy
The prize has two audiences. For origin-of-life researchers, the work shows that chemistry alone can break mirror symmetry and amplify the result, without invoking biology. It does not settle how homochirality actually arose on the early Earth: the Soai reaction requires reagents and water-free conditions that are implausible for a prebiotic world, as Caltech’s Furkan Öztürk noted. Its value is as proof of principle.
For industry, the significance is immediate. In many drugs only one enantiomer has the desired therapeutic effect, while the other may be inactive or cause harmful side effects; the Nobel committee said the discoveries “have been decisive for chemists who design reactions for the manufacture of pharmaceuticals”. Thalidomide remains the most cited cautionary tale. Regulators now expect companies to characterise each enantiomer separately, and single-enantiomer versions of older drugs — esomeprazole, escitalopram and levocetirizine among them — are commonplace. Understanding non-linear effects helps chemists design catalytic processes that deliver high purity efficiently, reducing waste from separating unwanted mirror images.
The prize also continues a lineage. In 2001 the chemistry Nobel went to William Knowles, Ryoji Noyori and Barry Sharpless for catalytically controlled asymmetric reactions. Recalling that award, the Royal Society of Chemistry’s president, Robert Mokaya, said it was good to see Kagan’s contributions to the field now recognised.
The Indian connection
India’s pharmaceutical industry, concentrated heavily in Hyderabad and Visakhapatnam, is among the world’s largest producers of active pharmaceutical ingredients, many of them chiral. Asymmetric catalysis, chiral resolution and enantiomer analysis are routine competences in the process-chemistry laboratories of Telangana and Andhra Pradesh, and institutions such as CSIR-IICT in Hyderabad have long research programmes in asymmetric synthesis. As Indian companies seek to move from generics towards original molecules, the ability to make the right hand of a molecule cheaply and cleanly is a competitive necessity, not an academic nicety.
Kagan, at 95, joins the ranks of the oldest Nobel laureates in any science. The award to him and to Soai is a reminder that some of chemistry’s deepest questions are answered not in single breakthroughs but over decades of patient work on how molecules behave.
–Vemuri Madhav Kumar
Key facts
- Laureates: Henri B. Kagan (95; Université Paris-Sud/Paris-Saclay, Orsay, France) and Kenso Soai (Tokyo University of Science, Japan)
- Citation: “for the discovery of non-linear effects and autocatalysis in asymmetric organic synthesis”
- Kagan: non-linear effect in asymmetric catalysis, mid-1980s; earlier DIOP ligand
- Soai: asymmetric autocatalysis (the Soai reaction), Nature 378, 767 (1995); ~2% → ~87% enantiomeric excess
- Prize: SEK 12 million, shared; announced 7 Oct 2026
